Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 6/20 | 0.34 |
| ▸ | BCHE | P06276 | 5/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390941 | 0.88 | ALDH1A1 (0.47) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL13619996 | 0.83 | GAA (0.42) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL2391310 | 0.81 | HTT (0.40) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL13625662 | 0.79 | MAPT (0.43) | GAAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL2390032 | 0.78 | OPRK1 (0.42) | ALDH1A1KMT2AUSP2HPGDHTT | |
| SCHEMBL2389189 | 0.78 | LMNA (0.46) | ALDH1A1MAPTKDM4EKMT2ALMNA | |
| SCHEMBL8987949 | 0.78 | BCHE (0.38) | GAAALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL11995845 | 0.78 | LMNA (0.46) | ALDH1A1MAPTKDM4EKMT2ALMNA | |
| SCHEMBL1411689 | 0.77 | KDM1A (0.48) | ALDH1A1MAPTMAOB | |
| SCHEMBL13625551 | 0.77 | BCHE (0.38) | GAAALDH1A1MAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | GOT1, GOT2, NDUFA7 | GAA 547/4885ALDH1A1 153/4885MAPT 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.